Avalo Therapeutics Files 8-K for Financials and Exhibits
Ticker: AVTX · Form: 8-K · Filed: Jul 9, 2024 · CIK: 1534120
| Field | Detail |
|---|---|
| Company | Avalo Therapeutics, INC. (AVTX) |
| Form Type | 8-K |
| Filed Date | Jul 9, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financials, filing
Related Tickers: AVTX
TL;DR
AVTX filed an 8-K for financials & exhibits. Nothing major reported.
AI Summary
On July 9, 2024, Avalo Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's financial statements and exhibits, with no other specific events or material changes detailed in the provided text.
Why It Matters
This filing indicates Avalo Therapeutics is providing updated financial information and exhibits to the SEC, which is standard procedure for public companies.
Risk Assessment
Risk Level: low — The filing is a routine submission of financial statements and exhibits, not indicating any new risks or significant operational changes.
Key Players & Entities
- Avalo Therapeutics, Inc. (company) — Registrant
- Cerecor Inc. (company) — Former company name
- July 9, 2024 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing by Avalo Therapeutics?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits'.
What was Avalo Therapeutics' former company name?
Avalo Therapeutics, Inc. was formerly known as Cerecor Inc.
On what date was this 8-K report filed?
This 8-K report was filed on July 9, 2024.
In which state is Avalo Therapeutics incorporated?
Avalo Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Avalo Therapeutics?
The principal executive office address for Avalo Therapeutics is 540 Gaither Road, Suite 400, Rockville, Maryland 20850.
Filing Stats: 434 words · 2 min read · ~1 pages · Grade level 11 · Accepted 2024-07-09 07:17:21
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 Par Value AVTX Nasdaq Capital Market
Filing Documents
- avtx-20240709.htm (8-K) — 25KB
- ex-991009ind.htm (EX-99.1) — 15KB
- avalologoa.jpg (GRAPHIC) — 8KB
- 0001628280-24-031426.txt ( ) — 174KB
- avtx-20240709.xsd (EX-101.SCH) — 2KB
- avtx-20240709_lab.xml (EX-101.LAB) — 21KB
- avtx-20240709_pre.xml (EX-101.PRE) — 12KB
- avtx-20240709_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On July 9, 2024, Avalo Therapeutics, Inc. (the "Company") issued a press release announcing that the Investigational New Drug ("IND") for AVTX-009, an anti-IL-1 monoclonal antibody (mAb), for the treatment of hidradenitis suppurativa ("HS") is now active. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Press Release dated July 9, 2024. 104 The cover pages of this Current Report on Form 8-K, formatted in Inline XBRL. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVALO THERAPEUTICS, INC. Date: July 9, 2024 By: /s/ Christopher Sullivan Christopher Sullivan Chief Financial Officer 2